OLMEDIPIN PLUS® F.C.TAB (40+5+12.5)MG/TAB Greċja - Grieg - Εθνικός Οργανισμός Φαρμάκων

olmedipin plus® f.c.tab (40+5+12.5)mg/tab

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - olmesartan medoxomil; amlodipine besylate; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (40+5+12.5)mg/tab - olmesartan medoxomil 40mg; amlodipine besylate 6,95mg; hydrochlorothiazide 12,5mg - olmesartan medoxomil, amlodipine and hydrochlorothiazide

OLMEDIPIN PLUS® F.C.TAB (40+10+12.5)MG/TAB Greċja - Grieg - Εθνικός Οργανισμός Φαρμάκων

olmedipin plus® f.c.tab (40+10+12.5)mg/tab

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - olmesartan medoxomil; amlodipine besylate; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (40+10+12.5)mg/tab - olmesartan medoxomil 40mg; amlodipine besylate 13,9mg; hydrochlorothiazide 12,5mg - olmesartan medoxomil, amlodipine and hydrochlorothiazide

OLMEDIPIN PLUS® F.C.TAB (40+5+25.0)MG/TAB Greċja - Grieg - Εθνικός Οργανισμός Φαρμάκων

olmedipin plus® f.c.tab (40+5+25.0)mg/tab

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - olmesartan medoxomil; amlodipine besylate; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (40+5+25.0)mg/tab - olmesartan medoxomil 40mg; amlodipine besylate 6,95mg; hydrochlorothiazide 25mg - olmesartan medoxomil, amlodipine and hydrochlorothiazide

SALMETEROL + FLUTICASONE/MYLAN 25MCG/250MCG PRESSURISED INHALATION, SUSPENSION Ċipru - Grieg - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

salmeterol + fluticasone/mylan 25mcg/250mcg pressurised inhalation, suspension

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg/250mcg - salmeterol xinafoate (8000001995) 0,0363mg; fluticasone propionate (8000031552) 0,25mg

SALMETEROL + FLUTICASONE/MYLAN 25MCG/125MCG PRESSURISED INHALATION, SUSPENSION Ċipru - Grieg - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

salmeterol + fluticasone/mylan 25mcg/125mcg pressurised inhalation, suspension

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg/125mcg - salmeterol xinafoate (8000001995) 0,0363mg; fluticasone propionate (8000031552) 0,125mg

APIXABAN/MYLAN 5MG FILM COATED TABLETS Ċipru - Grieg - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

apixaban/mylan 5mg film coated tablets

mylan ireland limited (0000011082) unit 35/36, grange parade, baldoyle industrial estate, dublin 13 - apixaban - film coated tablets - 5mg - apixaban (0503612473) 5mg

APIXABAN/MYLAN F.C.TAB 2.5MG/TAB Greċja - Grieg - Εθνικός Οργανισμός Φαρμάκων

apixaban/mylan f.c.tab 2.5mg/tab

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - apixaban - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 2.5mg/tab - apixaban 2,5mg - apixaban

APIXABAN/MYLAN F.C.TAB 5MG/TAB Greċja - Grieg - Εθνικός Οργανισμός Φαρμάκων

apixaban/mylan f.c.tab 5mg/tab

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - apixaban - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 5mg/tab - apixaban 5mg - apixaban

Lextemy Unjoni Ewropea - Grieg - EMA (European Medicines Agency)

lextemy

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Αντινεοπλασματικοί παράγοντες - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Sitagliptin / Metformin hydrochloride Mylan Unjoni Ewropea - Grieg - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.